Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One pill to tackle two heart risks: triple combo tested

NCT ID NCT03860220

Disease control Sponsor: Hyo-Soo Kim Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested a single pill containing three medicines (telmisartan, amlodipine, and rosuvastatin) in 252 Korean adults with both high blood pressure and high cholesterol. Participants took either the triple pill or a two-drug pill for 8 weeks. The study measured changes in blood pressure and LDL cholesterol to see if the triple combination works better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Telmisartan/Amlodipine/Rosuvastatin (triple combination pill)
What this could lead to
If successful, this could offer a simpler once-daily pill to manage both high blood pressure and high cholesterol together.
What could go wrong
This is a completed Phase 4 trial, so results are already known. The main risk is that the triple pill may not be more effective or safer than existing two-drug combinations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

252 people

The number who actually took part.

Started

Apr 2019

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 145 mmHg ≤ msSBP ≤ 190 mmHg * Triglycerides \< 500 mg/dL * LDL-C ≤ 250 mg/dL Exclusion Criteria: * sSBP ≥ 20mmHg and sDBP ≥ 10mmHg * symptomatic orthostatic hypotension and secondary/iatrogenic hypertension and dyslipidemia * history of moderate to severe cerebral ischemia, cerebral hemorrhage, transient ischemic attack, myocardial infarction, or unstable angina in the past 6 months; severe heart failure (New York Heart Association functional class III and IV) * hypersensitivity to telmisartan or rosuvastatin * history of angioedema after treatment with angiotensin-converting enzyme inhibitors or ARBs; creatinine phosphokinase levels ≥3 times the upper limit of normal * estimated glomerular filtration rate ≤30 mL/min; aspartate aminotransferase and alanine aminotransferase levels ≥3 times the upper limit of normal * potassium levels \>5.5 mmol/L; or any diseases that could affect the results of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemias are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias hyperlipidemia hypertensive disorder inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemias Hypertension

Contacts and locations

Locations

  • CHA Bundang Medical Center, CHA University

    Seongnam-si, Gyeonggi-do, 13496, South Korea

  • Hallym University Kangnam Sacred Heart Hospital

    Seoul, South Korea

  • Hallym University Sacred Heart Hospital

    Anyang-si, Gyeonggi-do, 14068, South Korea

  • Kangwon National University Hospital

    Chuncheon, Gangwon-do, 24289, South Korea

  • Korea University Ansan Hospital

    Ansan, Gyeonggi-do, 15355, South Korea

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Yeungnam University Hospital

    Daegu, 42415, South Korea

  • Yonsei University Wonju Severance Christian Hospital

    Wŏnju, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.